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A B S T R A C T
Introduction: Warm needle acupuncture (WA) is widely used the treatment in the East Asian countries.
However, there is no critically appraised evidence of the potential beneﬁts and harms. The purpose of this
systematic review will be to evaluate the efﬁcacy of WA for osteoarthritis (OA).
Methods and analysis: Electronic databases will be searched: MEDLINE, EMBASE, the Cochrane Central
Register of Controlled Trials (CENTRAL) and AMED, 6 Korean medical databases (Korea Med, the Korean
Traditional Knowledge Portal, OASIS, DBPIA, the Research Information Service System and the Korean
Studies Information Service System), 3 Chinese databases (CNKI, VIP and Wanfang) and a Japanese
database (CiNii Articles) will be searched from their inception. These will be searched from their
inception. Selection of the studies and data extraction and validation will be performed independently by
two reviewers. Randomised controlled trials (RCTs) and quasi-RCTs using WA for any type of OA will be
considered. The studies will independently undertake study selection, extraction of data and assessment
of study quality by two authors. Risk of bias will be assessed using the Cochrane risk of bias standards. All
data synthesis and subgroup analyses will be conducted using Review Manager Software.
Dissemination: Findings will be published in a peer-reviewed journals. This systematic review may inform
the treatment of OA patients in clinical practice.
ã 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1.1. Description of the condition
Osteoarthritis (OA) is a structural and functional failure of
whole joint [1] and damage to joint cartilage, deterioration of the
bone beneath the joint, swelling of the joint with newly formed
bone, and mild inﬂammation of the synovial membrane [2]. Above
all, OA is often associated with signiﬁcant disability and reduction
in quality of life [3]. This affects such as the knees, hips, ﬁngers and
lower spine. Researchers have reported that the knee joint is
affected especially frequently, and the incidence of knee OA is
increasing [4]. Unfortunately, the available treatments for OA are
not perfect. Therefore, many studies, both pharmacological and$ Trial registration number: PROSPERO 2015: CRD42015024413
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patient’s daily functioning [5].
1.2. Description of the intervention
Acupuncture and moxibustion have been used as medical
treatments in East Asia, including China, Korea and Japan [6].
Moxibustion includes various techniques. There are two types of
moxibustion: predominantly divided into direct moxibustion and
indirect moxibustion. When performing direct moxibustion, moxa
sticks are burnt at acupoints directly on the skin. In contrast, in
indirect moxibustion, the moxa cone does not touch the skin and is
burnt while being insulated from the skin by some substance [7].
Warm needle acupuncture (WA) is the combination of acupunc-
ture with moxibustion by stimulating acupoints with a burning
moxa (also called Ai Ye) stick on the handle of the acupuncture
needle [8]. The use of WA was ﬁrst documented in Shang Han Za
Bing Lun (“Discussion of Cold-Induced Disorders”), a classical Chinese
medical book by Zhongjing Zhang (Eastern Han dynasty, 25–220 C.
E.) [9]. WA is often used to treat painful conditions such as arthritis,article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
J.H. Jun et al. / European Journal of Integrative Medicine 8 (2016) 402–406 403especially rheumatoid arthritis and OA [10,11] as well as
musculoskeletal pain conditions [12,13]. WA treatment is trans-
mitted to the acupoint by radiation, moreover, by direction
conduction through the shaft of the needle, thereby stimulating
deep tissue within the acupoint and warming the acupoint on the
surface [14].
1.3. How the intervention might work
WA for OA is widely used for treatment and prevention [15,16].
Studies on the treatment of WA on OA have also shown a greater
pain relief compared to manual acupuncture [17]. Furthermore,
WA has reduced joint ﬂuid and abnormally high serum levels of
interleukin-1 beta (IL-1b) and tumor necrosis factor-alpha (TNF-
a), two inﬂammatory factors in patients with knee OA [18].
1.4. Why it is important to do this review
Many studies have been reported treatment using WA
treatment for OA in clinical practice [19,20]. One recent review
assessed the efﬁcacy of WA for OA but most of included studies
have suffered from high risk of bias [21]. The previous review
focused on the WA treatment for knee OA and searched Chinese
databases only. Furthermore, the review is outdated. Therefore, the
aim of this systematic review is to update, complete and critically
evaluate the evidence from randomized clinical trials (RCTs) of WA
for OA.
2. Methods
2.1. Study registration
This protocol review has been registered on PROSPERO 2015
(registration number CRD42015024413) [22].
2.2. Criteria for considering studies for this review
2.2.1. Types of studies
This systematic review will only include RCTs and quasi-RCTs.
Observational, cohort, case reports, case series, non-RCT, animal
and experimental studies will be excluded. No language restric-
tions will be imposed.
2.2.2. Types of participants
Patients suffering from OA will be included regardless of joint
location (e.g., chronic condition of the neck, near the ends of the
ﬁngers, at the base of the thumb, back, hip, and knee). We will also
include patients with both sexes and any age. Included patients
will have been diagnosed with OA according to the American
College of Rheumatology (ACR) criteria [23–25], the equivalent
European League Against Rheumatism (EULAR) criteria [26–28], or
the Clinical Guideline of New Drugs for Traditional Chinese
Medicine [29]. Studies will be excluded if they include patients
with rheumatoid arthritis, ankylosing arthritis, joint tuberculosis,
purulent arthritis, allergic arthritis, Kashin-Beck disease or
Podagra.
2.2.3. Types of interventions and controls
Studies that evaluate WA as the sole intervention will be
included. Warm needle will be deﬁned as moxa being attached to
the needle once it is inserted. Traditionally, traditional medicine
practitioners usually attach burning moxa to the handle of the AT
needle to improve the effectiveness of the therapy. Electro-
warmed needles and infrared radiation will be excluded. The
combined intervention include western medicine or rehabilita-
tion or physiotherapy, but exclude alternative therapy such asherbal medicine, Tuina, acupuncture. A combined intervention
will include western medicine or rehabilitation or physiotherapy,
but will exclude any that combines other alternative therapies
such as herbal medicine, Tuina, as well as other types of
acupuncture.
2.2.4. Type of outcome measures
 Primary outcomes
1) Treatment efﬁcacy: the number of patients whose OA symp-
toms improved and treatment effectiveness.
2) Pain: associated scale measured on the visual analogue scale
(VAS) [30], Western Ontario and McMaster Universities
Arthritis Index (WOMAC) of pain [31], a numerical rating scale
(NRS), Verbal Rating Scale (VRS), the Faces Pain Scale-Revised
(FPS-R), etc.
3) Function of joint: measured by recognized scales including
Western Ontario and MacMaster universities arthritis index
(WOMAC), Lequesne score, etc.
 Secondary outcomes
1) Quality of life (QoL): measured using a validated questionnaire,
such as the short-form (36-item) health survey (SF-36) [32] or
another validated scale.
2) Adverse events.
2.3. Search method for identifying the studies
2.3.1. Electronic searches
Electronic databases will be searched from their inception and
will include MEDLINE, EMBASE, the Cochrane Central Register of
Controlled Trials (CENTRAL) and AMED, 6 Korean databases (Korea
Med, the Korean Traditional Knowledge Portal, OASIS, DBPIA, the
Research Information Service System and the Korean Studies
Information Service System), 3 Chinese Databases (CNKI, VIP and
Wanfang), and the Japanese database (CiNii Articles). The search
strategy will include warm needing acupuncture in English,
Chinese and Korean.
2.3.2. Searches of other resources
The authors will scan the reference lists and retrieve additional
studies. In addition, authors will search the WHO International
Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/) and Google Scholar (http://scholar.google.co.kr/).
Dissertations of degrees will be included. The ClinicalTrials.gov
registry (http://clinicaltrials.gov/) will be searched for any
unpublished trials.
2.3.3. Search strategy
The strategy for searching MEDLINE is described in Appendix A.
The strategy for searching CNKI is described in Appendix B. Similar
search strategies will be applied to other databases.
2.4. Data collection, extraction and assessment
2.4.1. Selection of studies
Two reviewers (JHJ and TYC) will independently screen the
titles and abstracts for searched studies, and perform study
selection and record their decisions according to predeﬁned
criteria. Another reviewers (MSL) will resolve disagreements of
section study. Study selection will be documented and summarised
in Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) ﬂow diagram [33].
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Two reviewers (JHJ and TYC) will read studies and indepen-
dently extract the data using a standard data extraction form. The
form will be comprised of type of OA, participants, intervention
group treatment, control group treatment, outcome and result.
Disagreements of section study will be resolved by another
reviewers (MSL). We will use Grading of Recommendations
Assessment, Development and Evaluation (GRADE) software to
judge the quality of evidence for data from Cochrane Systematic
Reviews to create a Summary of Findings table [34]. Additionally,
the details of the treatment regimens will be summarised in a
table. When reported data are insufﬁcient or unclear, an author
will contact the ﬁrst author or corresponding authors by e-mail or
telephone to request missing or clariﬁcation data.
2.4.3. Assessment of risk of bias
The quality of included studies will be assessed according to the
criteria described in the Cochrane Handbook for Systematic
Reviews of Intervention [35]. The following items will be assessed:
1) random sequence generation; 2) allocation concealment; 3)
blinding of participants and personnel; 4) blinding of outcome
assessment; 5) completeness of outcome data; 6) completeness of
reporting; 7) other sources of bias. Each trial will be categorized as
having a low (L), unclear (U), or high (H) risk of bias. If necessary,
we will contact the authors of assessed trials for clariﬁcation. We
will resolve any differences in opinion through discussion or
consultation with all of the authors.
2.4.4. Data synthesis
All statistical analyses will be performed using the Review
Manager (Cochrane Collaboration Software, RevMan) version 5.3.
For dichotomous data, we will present the treatment effects and
use the risk ratios (RR) with 95% conﬁdence intervals (CIs). For the
continuous data, we will use the mean differences (MD) with 95%
CIs. If outcome variables are measured on different scales, we will
use a standard mean differences (SMD) analysis with 95% CIs.
2.4.5. Unit of analysis issues
The systematic review will include data from parallel-group
studies for the meta-analysis. For cross-over trials, the ﬁrst
treatment period of data will be analyzed. In that case if there is
more than one control group, each group will constitute a separate
unit of analysis. If there are multiple treatment time observations,
the data will be analysed as either short term (within 30days) or
long term (over 30days). In addition, analysis will be divided into
various types of OA.
2.4.6. Assessment of heterogeneity
We will use a ﬁxed model if there is no evidence of
heterogeneity; if not we will apply random effect model. If a
meta-analysis is possible, we will use the I2 statistic for quantifying
inconsistencies across the included studies. A result 50% cut off
point would represent substantial heterogeneity. If heterogeneity
is observed, we will conduct subgroup analyses [36].
2.4.7. Subgroup analysis and the investigation of heterogeneity
If studies and data are sufﬁcient, subgroup analyses will be
conducted according to:
a Type of OA (e.g, knees, hip, back or ﬁngers)
b Type of control intervention (e.g, western medicine, no
treatment or usual care)2.4.8. Sensitivity analysis
We will use sensitivity analyses to investigate suspected funnel
plot asymmetry. Sensitivity analysis will be conducted according to
the following criteria:
1.) Methodological qualities (sequence generation, allocation
concealment, or blinding in the assessment of outcomes and
symptom severity)
2.) Sample size (more or less than 40 participants in each group)
In the analysis, we will exclude high risk of bias studies and
compare the results with those using the worst-case scenario to
combine studies. Then we will have a discussion to decide whether
the high risk of bias studies should be excluded on the bias of
sample size, strength of evidence and inﬂuence on pooled effect
size.
2.4.9. Assessment of reporting biases
If more than 10 studies are available, we will conduct funnel
plot for publication bias and small study effects using Egger’s
method. Funnel plot asymmetry is certainly not same as
publication bias. We will attempt to distinguish the possible
reasons for the asymmetry, therefore, included poor methodologi-
cal quality and true heterogeneity of studies [37].
3. Discussion
This protocol for a systematic review will provide a detailed
summary of the current state of evidence regarding the effective-
ness of the WA in treating the symptoms of patients with OA. The
review will be useful to patients and healthcare providers in
determining the appropriate role of WA in the treatment of OA.
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Appendix A. MEDLINE search strategy(PubMed)
#1. exp osteoarthritis/
#2. osteoarthr*.tw
#3. (degenerative adj2 arthritis).mp.
#4. arthrosis.mp.
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#6. exp acupuncture therapy/
#7. warm needle thechinique.mp.
#8. warm needle acupuncture.mp
#9. warm needle moxibustion.mp
#10. warm-needling. mp
#11. wen zhen. mp
#12. warm$ acupuncture. mp
#13. or/#6-12
#14. exp Randomized Controlled Trials as Topic/
#15. exp Clinical Trials as Topic/
#16. exp controlled clinical trials as topic/
#17. (randomized controlled trial* or controlled clinical trial* or
randomized* or randomly* or placebo or clinical trial* or controlled
trial*).mp.
#18. or/#14  17
#19. #5 and #13and #18
Appendix B. CNKI search stratege
#1. ⏽䩜
#2. ⏽䩜♌
#3. warm acupuncture
#4. warm needle acupuncture
#5. warming needle moxibustion
#6./or #1-5
#7.偼݇㡖♢
#8. osteoarthritis OR osteoarthrosis OR ostearthritis OR
Degenerative Osteoarthritis OR Knee osteoarthritis OR Hip
Osteoarthritis OR spine osteoarthritis OR Lumbar Spine Osteoar-
thritis OR Primary Hypertrophic Osteoarthropathy OR Atlantoxial
Osteoarthritis OR senior osteoarthritis OR anteromedial osteoar-
thritis OR advanced osteoarthritis OR hand osteoarthritis
#9. OA OR KOA
#10. or/#7-9
#11. 随机
#12.
#13. Randomized trials
#14. or/#11-13
#15. #6 and #10 and #14
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